transitional cell carcinoma

Summary

Summary: A malignant neoplasm derived from transitional epithelium, occurring chiefly in the urinary bladder, ureters or renal pelves (especially if well differentiated), frequently papillary. Transitional cell carcinomas are graded 1 to 3 or 4 according to the degree of anaplasia, grade 1 appearing histologically benign but being liable to recurrence. (Stedman, 25th ed)

Top Publications

  1. ncbi Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer
    Hans von der Maase
    Department of Oncology, Aarhus University Hospital, DK 8000 Aarhus C, Denmark
    J Clin Oncol 23:4602-8. 2005
  2. ncbi Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study
    H von der Maase
    Aarhus University Hospital, Denmark
    J Clin Oncol 18:3068-77. 2000
  3. ncbi Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients
    J P Stein
    Department of Urology, University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, CA 90089, USA
    J Clin Oncol 19:666-75. 2001
  4. pmc Loss of prostasin (PRSS8) in human bladder transitional cell carcinoma cell lines is associated with epithelial-mesenchymal transition (EMT)
    Li Mei Chen
    Department of Molecular Biology, Burnett School of Biomedical Sciences, University of Central Florida College of Medicine, Orlando, Florida 32816, USA
    BMC Cancer 9:377. 2009
  5. ncbi Urinary interleukin-8 levels are elevated in subjects with transitional cell carcinoma
    Elinore Sheryka
    Section of Urology, Yale University School of Medicine, New Haven, Connecticut 06520 8041, USA
    Urology 62:162-6. 2003
  6. ncbi FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma
    Adel H Jebar
    Cancer Research UK Clinical Centre, St James s University Hospital, Beckett Street, Leeds LS9 7TF, UK
    Oncogene 24:5218-25. 2005
  7. pmc Inactivation of p53 and Pten promotes invasive bladder cancer
    Anna M Puzio-Kuter
    Department of Urology, Columbia University, College of Physicians and Surgeons, New York, New York 10032, USA
    Genes Dev 23:675-80. 2009
  8. ncbi Contemporary management of stage T1 transitional cell carcinoma of the bladder
    Mark S Soloway
    Department of Urology, University of Miami, Miami, Florida, USA
    J Urol 167:1573-83. 2002
  9. doi Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract
    Joaquim Bellmunt
    Department of Medical Oncology, University Hospital del Mar, Passeig Maritim 25 29, E 08003 Barcelona, Spain
    J Clin Oncol 27:4454-61. 2009
  10. ncbi Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial
    Luigi Dogliotti
    Unit of Medical Oncology, University of Torino, San Luigi Hospital, Orbassano Torino, Italy
    Eur Urol 52:134-41. 2007

Detail Information

Publications289 found, 100 shown here

  1. ncbi Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer
    Hans von der Maase
    Department of Oncology, Aarhus University Hospital, DK 8000 Aarhus C, Denmark
    J Clin Oncol 23:4602-8. 2005
    To compare long-term survival in patients with locally advanced or metastatic transitional cell carcinoma (TCC) of the urothelium treated with gemcitabine/cisplatin (GC) or methotrexate/vinblastine/doxorubicin/cisplatin (MVAC).
  2. ncbi Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study
    H von der Maase
    Aarhus University Hospital, Denmark
    J Clin Oncol 18:3068-77. 2000
    ..Gemcitabine plus cisplatin (GC) and methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) were compared in patients with locally advanced or metastatic transitional-cell carcinoma (TCC) of the urothelium...
  3. ncbi Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients
    J P Stein
    Department of Urology, University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, CA 90089, USA
    J Clin Oncol 19:666-75. 2001
    ....
  4. pmc Loss of prostasin (PRSS8) in human bladder transitional cell carcinoma cell lines is associated with epithelial-mesenchymal transition (EMT)
    Li Mei Chen
    Department of Molecular Biology, Burnett School of Biomedical Sciences, University of Central Florida College of Medicine, Orlando, Florida 32816, USA
    BMC Cancer 9:377. 2009
    ..The aim of this study was to evaluate prostasin expression states in the transitional cell carcinomas (TCC) of the human bladder and in human TCC cell lines...
  5. ncbi Urinary interleukin-8 levels are elevated in subjects with transitional cell carcinoma
    Elinore Sheryka
    Section of Urology, Yale University School of Medicine, New Haven, Connecticut 06520 8041, USA
    Urology 62:162-6. 2003
    ..Although many studies have indicated that IL-8 is increased in infectious/inflammatory processes, elevated levels of IL-8 in urine also may be indicative of active transitional cell carcinoma (TCC).
  6. ncbi FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma
    Adel H Jebar
    Cancer Research UK Clinical Centre, St James s University Hospital, Beckett Street, Leeds LS9 7TF, UK
    Oncogene 24:5218-25. 2005
    ..If these events have biological equivalence, Ras mutant invasive UCC may represent a novel subgroup...
  7. pmc Inactivation of p53 and Pten promotes invasive bladder cancer
    Anna M Puzio-Kuter
    Department of Urology, Columbia University, College of Physicians and Surgeons, New York, New York 10032, USA
    Genes Dev 23:675-80. 2009
    ..Our integrated analyses of mouse and human bladder cancer provide a rationale for investigating mTOR inhibition for treatment of patients with invasive disease...
  8. ncbi Contemporary management of stage T1 transitional cell carcinoma of the bladder
    Mark S Soloway
    Department of Urology, University of Miami, Miami, Florida, USA
    J Urol 167:1573-83. 2002
    b>Transitional cell carcinoma involving the lamina propria (stage T1) is associated with a high recurrence and progression rate with implications for patient survival and quality of life...
  9. doi Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract
    Joaquim Bellmunt
    Department of Medical Oncology, University Hospital del Mar, Passeig Maritim 25 29, E 08003 Barcelona, Spain
    J Clin Oncol 27:4454-61. 2009
    Vinflunine (VFL) is a new microtubule inhibitor that has activity against transitional cell carcinoma of urothelial tract (TCCU)...
  10. ncbi Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial
    Luigi Dogliotti
    Unit of Medical Oncology, University of Torino, San Luigi Hospital, Orbassano Torino, Italy
    Eur Urol 52:134-41. 2007
    ..the efficacy of gemcitabine-cisplatin (GP) and gemcitabine-carboplatin (GC) in patients with advanced transitional cell carcinoma of the urothelium (TCC), with the main objective to demonstrate a reduction in toxicity of at least 25% ..
  11. ncbi Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium
    Shahrokh F Shariat
    Department of Urology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA
    J Urol 176:2414-22; discussion 2422. 2006
    We present the characteristics and outcomes of a large, contemporary, consecutive series of patients treated with radical cystectomy and pelvic lymphadenectomy for transitional cell carcinoma of the bladder.
  12. doi Biological heterogeneity of putative bladder cancer stem-like cell populations from human bladder transitional cell carcinoma samples
    Angela Bentivegna
    Dipartimento di Neuroscienze e Tecnologie Biomediche, Universita degli Studi di Milano Bicocca, Monza, Italy
    Cancer Sci 101:416-24. 2010
    b>Transitional cell carcinoma (TCC) is the most common type of bladder cancer...
  13. ncbi Prostate stem cell antigen is overexpressed in human transitional cell carcinoma
    N Amara
    Department of Urology, Jonsson Cancer Center, University of California Los Angeles School of Medicine, Los Angeles, California 90095, USA
    Cancer Res 61:4660-5. 2001
    ..in normal and malignant urothelial tissues to assess its potential as an immunotherapeutic target in transitional cell carcinoma (TCC)...
  14. ncbi Incidence of transitional cell carcinoma and arsenic in drinking water: a follow-up study of 8,102 residents in an arseniasis-endemic area in northeastern Taiwan
    H Y Chiou
    School of Public Health, Taipei Medical University, Taipei, Taiwan
    Am J Epidemiol 153:411-8. 2001
    ..In 1991-1994, the authors examined risk of transitional cell carcinoma (TCC) in relation to ingested arsenic in a cohort of 8,102 residents in northeastern Taiwan...
  15. ncbi A second-look TUR in T1 transitional cell carcinoma: why?
    Gerhard Jakse
    Urological Clinic, University Clinic of RWTH Aachen, Pauwelsstrasse 30, D 520570 Aachen, Germany
    Eur Urol 45:539-46; discussion 546. 2004
    ..Currently, there is no standard appropriate treatment of T1 tumors. However, we strongly recommend that future studies on the conservative treatment of T1 tumors include a second TUR within 2 to 4 weeks after the first one...
  16. ncbi Correlation of cyclooxygenase-2 expression with molecular markers, pathological features and clinical outcome of transitional cell carcinoma of the bladder
    Shanrokh F Shariat
    Scott Department of Urology, Baylor College of Medicine, 6560 Fannin, Houston, TX 77030, USA
    J Urol 170:985-9. 2003
    ..relationship between cyclooxygenase-2 (COX-2) expression and molecular alterations commonly found in transitional cell carcinoma (TCC) of the bladder and determined whether COX-2 immunoreactivity is associated with cancer stage, ..
  17. ncbi Fibroblast growth factors and their receptors in transitional cell carcinoma
    Nicholas P Munro
    Cancer Research United Kingdom Clinical Centre in Leeds, St James s University Hospital, Leeds, United Kingdom
    J Urol 169:675-82. 2003
    The recent identification in transitional cell carcinoma of mutations in a fibroblast growth factor (FGF) receptor, namely FGF receptor-3, has provoked great interest in the potential usefulness of FGF receptors and their ligands as ..
  18. ncbi Preoperative plasma levels of interleukin-6 and its soluble receptor predict disease recurrence and survival of patients with bladder cancer
    Ben Andrews
    Scott Department of Urology, Baylor College of Medicine and The Methodist Hospital, Houston, Texas, USA
    J Urol 167:1475-81. 2002
    ..We tested the hypothesis that preoperative plasma IL-6 and IL-6sR levels would predict cancer stage and prognosis in patients with transitional cell carcinoma of the bladder.
  19. ncbi Second transurethral resection of superficial transitional cell carcinoma of the bladder: a must even for experienced urologists
    M A Zurkirchen
    Department of Urology, University Hospital Zurich, Zurich, Switzerland
    Urol Int 72:99-102. 2004
    ..urologists have a high percentage of persisting carcinoma after transurethral bladder tumour resection (TUR-B) the importance of a routine second resection in the management of transitional cell carcinoma (TCC) of the bladder is defined.
  20. doi A-FABP, a candidate progression marker of human transitional cell carcinoma of the bladder, is differentially regulated by PPAR in urothelial cancer cells
    Guillaume Boiteux
    Laboratoire de Biologie Cellulaire et Moleculaire, EA 3181 IBCT IFR No 133, Universite de Franche Comte, UFR des Sciences Médicales et Pharmaceutiques, Besançon Cedex 3, France
    Int J Cancer 124:1820-8. 2009
    ..c) 2008 Wiley-Liss, Inc...
  21. ncbi Chronic inflammation and bladder cancer
    Dominique S Michaud
    Department of Epidemiology, Harvard School of Public Health, Boston, MA 02115, USA
    Urol Oncol 25:260-8. 2007
    ..In developed countries, transitional cell carcinoma is the predominant type of bladder cancer, whereas in Schistosomiasis-endemic regions, squamous cell ..
  22. doi Clusterin as a diagnostic and prognostic marker for transitional cell carcinoma of the bladder
    Sahar M Hazzaa
    Clinical Pathology Department, Tanta University, Tanta, Egypt
    Pathol Oncol Res 16:101-9. 2010
    ..of profiling and measuring the concentration of clusterin in urine and serum for individuals with transitional cell carcinoma (TCC) of the bladder and comparing it with nontumor controls...
  23. ncbi Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies
    Maurizio Brausi
    Institute Sant Agostino, Estense, Modena, Italy
    Eur Urol 41:523-31. 2002
    ..To assess the variability between institutions in the recurrence rate at the first follow-up cystoscopy (RR-FFC) after transurethral resection (TUR) in patients with stage Ta T1 bladder cancer...
  24. ncbi Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder
    Jay D Raman
    Department of Urology, The New York Presbyterian Hospital, Weill Medical College of Cornell University, New York, New York 10021, USA
    Clin Cancer Res 11:8570-6. 2005
    ..We evaluated EZH2 mRNA and protein expression in bladder specimens from patients and the EZH2 mRNA expression in five bladder cancer cell lines...
  25. pmc Characterization of a novel transplantable orthotopic rat bladder transitional cell tumour model
    Z Xiao
    Department of Experimental Surgery, University of Alberta, Edmonton, Canada
    Br J Cancer 81:638-46. 1999
    ..To accomplish this, the established AY-27 rat bladder transitional cell carcinoma (TCC) cell line was transplanted orthotopically into Fischer CDF344 female rats...
  26. pmc Expression of cyclooxygenase-2 in human transitional cell carcinoma of the urinary bladder
    A Ristimaki
    Department of Pathology, Helsinki University Central Hospital, P O Box 140, FIN 00029 Helsinki, Finland
    Am J Pathol 158:849-53. 2001
    Recent studies suggest that expression of cyclooxygenase-2 (Cox-2) is elevated in transitional cell carcinoma (TCC) of the urinary bladder and that inhibition of Cox-2 activity suppresses bladder cancer in experimental animal models...
  27. ncbi Overexpression of the wild type p73 gene in human bladder cancer
    A Yokomizo
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota 55095, USA
    Oncogene 18:1629-33. 1999
    ..These data suggest that the p73 is unlikely to be a tumor suppressor gene, but that overexpression of p73 may contribute to tumorigenesis in bladder cancer...
  28. doi Large-scale real-time reverse transcription-PCR approach of angiogenic pathways in human transitional cell carcinoma of the bladder: identification of VEGFA as a major independent prognostic marker
    Géraldine Pignot
    Universite Paris Descartes, Faculte de Medecine, AP HP, Hopital Cochin, Department of Urology, Paris, F 75014 France
    Eur Urol 56:678-88. 2009
    ..Actors of the angiogenesis pathways are targets for the new promising targeted therapies already used in several malignancies. In bladder cancer, antiangiogenic molecules could also add to already existing treatment options...
  29. ncbi A nuclear form of the heparin-binding epidermal growth factor-like growth factor precursor is a feature of aggressive transitional cell carcinoma
    Rosalyn M Adam
    Departments of Urology and Surgery, Children s Hospital Boston and Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer Res 63:484-90. 2003
    ..In this study, we identify a potential role for proHB-EGF in transitional cell carcinoma (TCC) of the bladder...
  30. ncbi Endoscopic detection of transitional cell carcinoma with 5-aminolevulinic acid: results of 1012 fluorescence endoscopies
    D Zaak
    Department of Urology, Klinikum Grosshadern, Ludwig-Maximilians-University, Munich, Germany
    Urology 57:690-4. 2001
    ..7% of these additionally detected neoplastic foci had poorly differentiated histologic features. CONCLUSIONS: AFE has proved to be a clinically feasible procedure with an outstanding detection rate for flat, urothelial, high-risk lesions...
  31. ncbi T1G3 transitional cell carcinoma of the bladder: recurrence, progression and survival
    M Peyromaure
    Department of Urology, Cochin Hospital, Paris, France
    BJU Int 93:60-3. 2004
    ..To report our experience with T1G3 bladder tumours over the last 10 years...
  32. ncbi PTCH gene mutations in invasive transitional cell carcinoma of the bladder
    T W McGarvey
    Department of Surgery, University of Pennsylvania Medical Center and Veterans Administration Medical Center, Philadelphia 19104, USA
    Oncogene 17:1167-72. 1998
    ....
  33. ncbi Efficacy of selective estrogen receptor modulators in nude mice bearing human transitional cell carcinoma
    Guru Sonpavde
    U S Oncology Research, Webster, Texas, USA
    Urology 69:1221-6. 2007
    ..To evaluate estrogen receptors as a therapeutic target for human bladder cancer...
  34. ncbi Outcome of surgical resection of pulmonary metastasis from urinary tract transitional cell carcinoma
    Ryu Kanzaki
    Department of Thoracic Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, 1 3 3 Nakamichi, Higashinari ku, Osaka 537 8511, Japan
    Interact Cardiovasc Thorac Surg 11:60-4. 2010
    There is little information on pulmonary metastasectomy of urinary tract transitional cell carcinoma (TCC)...
  35. ncbi Ny-ESO-1 expression and immunogenicity associated with transitional cell carcinoma: correlation with tumor grade
    T Kurashige
    Department of Urology, Okayama University Medical School, Okayama 700-8558, Japan
    Cancer Res 61:4671-4. 2001
    NY-ESO-1 mRNA expression in transitional cell carcinoma was investigated by reverse transcription-PCR and immunohistochemistry. NY-ESO-1 mRNA was detected in 20 of 62 (32%) tumor specimens...
  36. doi Imaging and staging of transitional cell carcinoma: part 1, lower urinary tract
    Raghunandan Vikram
    Department of Diagnostic Radiology, The University of Texas M D Anderson Cancer Center, Houston, 77030 4009, USA
    AJR Am J Roentgenol 192:1481-7. 2009
    b>Transitional cell carcinoma (TCC) of the bladder is one of the most common malignancies affecting the genitourinary tract and is characterized by multifocality and a high incidence of recurrence...
  37. ncbi The management of urethral transitional cell carcinoma after radical cystectomy for invasive bladder cancer
    Peter E Clark
    Department of Urology, University of Southern California Norris Cancer Center, Los Angeles, California, USA
    J Urol 172:1342-7. 2004
    Previous reports have identified risk factors for urethral recurrence following radical cystectomy for transitional cell carcinoma (TCC). However, reports of the clinical presentation, treatment and outcome in these patients are lacking...
  38. ncbi Tumor lymphangiogenesis in transitional cell carcinoma of the upper urinary tract: association with clinicopathological features and prognosis
    Yasuyoshi Miyata
    Department of Urology, Nagasaki University Graduate School of Biomedical Science, Nagasaki 852 8501, Japan
    J Urol 176:348-53. 2006
    ..We investigated the clinical and prognostic significance of lymphangiogenesis in patients with transitional cell carcinoma of the upper urinary tract.
  39. ncbi Molecular biology of transitional cell carcinoma
    Sana Al-Sukhun
    Department of Internal Medicine, Division of Hematology Oncology, Wayne State University School of Medicine and The Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA
    Crit Rev Oncol Hematol 47:181-93. 2003
    b>Transitional cell carcinoma (TCC) is the fifth most common solid malignancy in the USA...
  40. ncbi Evaluation of cytotoxic effects induced by bcl-2 and bcl-xL antisense-oligodeoxynucleotides in normal urothelium and transitional cell carcinoma
    Ute Gabriel
    Department of Urology, Mannheim Medical Center, University of Heidelberg, 68167 Mannheim, Germany
    Oncol Rep 20:1419-23. 2008
    ..effects of bcl-2 and bcl-xL antisense-oligodeoxynucleotides (AS-ODNs) in benign urothelial and transitional cell carcinoma (TCC) cell lines...
  41. pmc The relationship between the systemic inflammatory response, tumour proliferative activity, T-lymphocytic infiltration and COX-2 expression and survival in patients with transitional cell carcinoma of the urinary bladder
    M Hilmy
    Department of Surgery, Royal Infirmary University, Glasgow G31 2ER, UK
    Br J Cancer 95:1234-8. 2006
    ..activity, T-lymphocytic infiltration, and COX-2 expression and survival was examined in patients with transitional cell carcinoma of the urinary bladder (n=103)...
  42. ncbi Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder
    Shahrokh F Shariat
    Scott Department of Urology, Baylor College of Medicine and Methodist Hospital, Houston, Texas, USA
    J Urol 169:938-42. 2003
    We describe cyclooxygenase-2 (COX-2) expression patterns in patients with carcinoma in situ and/or stage T1 transitional cell carcinoma. We determined whether expression is associated with clinical outcome in these patients.
  43. ncbi Heterogeneity of cellular proliferation within transitional cell carcinoma: correlation of protein kinase C alpha/betaI expression and activity
    Vesa Aaltonen
    Department of Anatomy and Cell Biology, University of Oulu, University of Oulu, Finland
    J Histochem Cytochem 54:795-806. 2006
    A total of 18 histological samples containing both transitional cell carcinoma (TCC) and normal urothelial epithelium were analyzed for protein kinase C (PKC)-alpha and -betaI expression, and for their phosphorylated substrates...
  44. ncbi Expression in bladder transitional cell carcinoma by real-time quantitative reverse transcription polymerase chain reaction array of 65 genes at the tumor suppressor locus 9q34.1-2: identification of 5 candidates tumor suppressor genes
    Najla Amira
    UroGene, Genopole, Evry, France
    Int J Cancer 111:539-42. 2004
    Frequent deletions on 9q34.1-2 were reported in bladder transitional cell carcinoma. High deletion mapping studies delimited a critical interval between markers D9S61 and D9S66, which is highly susceptible to contain a tumor suppressor ..
  45. ncbi Expression of LAT1 predicts risk of progression of transitional cell carcinoma of the upper urinary tract
    Kuniaki Nakanishi
    Department of Pathology and Laboratory Medicine, National Defense Medical College, Tokorozawa, 359 8513, Japan
    Virchows Arch 451:681-90. 2007
    ..In conclusion, the detection of the active form of LAT1 protein would appear to be of value in informing the risk of progression in transitional cell carcinoma of the upper urinary tract.
  46. ncbi Role of bone morphogenetic proteins in transitional cell carcinoma cells
    Isaac Yi Kim
    Division of Urologic Oncology, The Cancer Institute of New Jersey, 195 Little Albany Street 4560, New Brunswick, NJ 08903, USA
    Cancer Lett 241:118-23. 2006
    ..Herein, we review the data concerning BMPs in transitional cell carcinoma cells.
  47. ncbi Interleukin-4 gene intron-3 polymorphism is associated with transitional cell carcinoma of the urinary bladder
    Fuu Jen Tsai
    Department of Paediatrics, China Medical University Hospital, Taichung, Taiwan
    BJU Int 95:432-5. 2005
    ..the interleukin-4 gene exon 3, and of the interleukin-1beta gene exon 5 and promoter region, are associated with transitional cell carcinoma (TCC) of the urinary bladder, as cytokines are hypothesized to be important in cancer formation.
  48. ncbi Glut 1 expression in transitional cell carcinoma of the urinary bladder is associated with poor patient survival
    M Younes
    Department of Pathology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
    Anticancer Res 21:575-8. 2001
    ..Glut1 has been shown to be expressed in many human cancers, including transitional cell carcinoma of the urinary bladder (TCCB)...
  49. ncbi Molecular evolution and intratumor heterogeneity by topographic compartments in muscle-invasive transitional cell carcinoma of the urinary bladder
    S J Diaz-Cano
    Department of Pathology, St Bartholomew s and the Royal London School of Medicine and Dentistry, United Kingdom
    Lab Invest 80:279-89. 2000
    ..No differences in the immunohistochemical expression were observed, precluding a more extensive clinical application...
  50. ncbi Relation between cyclooxygenase-2 expression and tumor invasiveness and patient survival in transitional cell carcinoma of the urinary bladder
    T Shirahama
    Department of Urology, Kagoshima University, Sakuragaoka, Kagoshima, Japan
    Cancer 92:188-93. 2001
    Expression of the inducible form of cyclooxygenase (COX)-2 is known to correlate with development of transitional cell carcinoma (TCC) of the human urinary bladder...
  51. ncbi Evaluation of nuclear matrix protein 22 as a tumour marker in the detection of transitional cell carcinoma of the bladder
    M Sanchez-Carbayo
    Laboratorio de Marcadores Tumorales, Servicio de Analisis Clinicos, Hospital General Universitario de Alicante, Spain
    BJU Int 84:706-13. 1999
    ....
  52. ncbi Ureteral tumour: a specific upper urinary tract transitional cell carcinoma
    Willem Oosterlinck
    Eur Urol 51:1164-5. 2007
  53. pmc Correlation between human papillomavirus infection and bladder transitional cell carcinoma
    M R Barghi
    Shohada Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Urology and Nephrology Research Center, Tehran, Iran
    BMC Infect Dis 5:102. 2005
    To determine the association of human papillomavirus infection (HPV) and transitional cell carcinoma (TCC).
  54. doi Serum Th1 and Th2 cytokine balance in patients of superficial transitional cell carcinoma of bladder pre- and post-intravesical combination immunotherapy
    Abhilasha Agarwal
    Institute of Pathology ICMR, Safdarjung Hospital Campus, New Delhi, India
    Immunopharmacol Immunotoxicol 32:348-56. 2010
    ..with intravesical bacillus Calmette-Guerin (BCG) plus interferon-alpha2b (IFN-alpha2b) for superficial transitional cell carcinoma (TCC) seems to be immune-dependent and activation of Th1 immune response is required for clinical ..
  55. ncbi Oncologic outcomes for complete robot-assisted laparoscopic management of upper-tract transitional cell carcinoma
    Jonathan A Eandi
    Department of Urology, City of Hope, Duarte, California 91010, USA
    J Endourol 24:969-75. 2010
    The gold standard for treatment of upper-tract transitional cell carcinoma (TCC) is nephroureterectomy. For distal ureteral TCC, distal ureterectomy with ureteral reimplantation represents a treatment option...
  56. ncbi Transitional cell carcinoma of the ureter and renal pelvis
    Ziya Kirkali
    Department of Urology, Dokuz Eylul University School of Medicine, Inciralti, Izmir 35340, Turkey
    Crit Rev Oncol Hematol 47:155-69. 2003
    b>Transitional cell carcinoma (TCC) of ureter and renal pelvis is relatively uncommon. Smoking, occupational carcinogens, analgesic abuse, Balkan nephropathy are the risk factors...
  57. ncbi Upper urinary tract tumour after radical cystectomy for transitional cell carcinoma of the bladder: an update on the risk factors, surveillance regimens and treatments
    Kristin M Sanderson
    Urologic Oncology, Department of Urology, Keck School of Medicine, University of Southern California, USC Norris Cancer Center, Los Angeles, CA, USA
    BJU Int 100:11-6. 2007
    ..the genitourinary tract; approximately 3% of patients treated by radical cystectomy (RC) for invasive transitional cell carcinoma (TCC) of the bladder will subsequently develop a subsequent TCC in the upper urinary tract (UUT) ..
  58. doi SNPs of GSTM1, T1, P1, epoxide hydrolase and DNA repair enzyme XRCC1 and risk of urinary transitional cell carcinoma in southwestern Taiwan
    Ling I Hsu
    Genomics Research Center, Academia Sinica, 128 Academia Road Section 2, Nankang, Taipei, Taiwan
    Toxicol Appl Pharmacol 228:144-55. 2008
    ..area in southwestern Taiwan to examine the possible risk factors and genetic susceptibility for urinary transitional cell carcinoma (TCC)...
  59. ncbi Prognostic value of lymph node dissection in patients with muscle-invasive transitional cell carcinoma of the upper urinary tract
    Marco Roscigno
    Department of Urology, Vita Salute University San Raffaele, Milan, Italy
    Eur Urol 53:794-802. 2008
    To analyze the prognostic role of lymphadenectomy (LND) in patients with muscle-invasive transitional cell carcinoma (TCC) of the upper urinary tract (UUT) managed with radical surgery.
  60. pmc Proapoptotic genes BAX and CD40L are predictors of survival in transitional cell carcinoma of the bladder
    S A Hussain
    Cancer Research UK Institute for Cancer Studies, University of Birmingham, Edgbaston, UK
    Br J Cancer 88:586-92. 2003
    ..BCL2, BAX, P53, CD40 and CD40L in archival tissues of patients included in various treatment trials for transitional cell carcinoma (TCC) of the bladder...
  61. pmc Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine
    A Vlahou
    Departments of Microbiology and Molecular Cell Biology, Eastern Virginia Medical School, 700 W Olney Rd, Norfolk, VA 23507, USA
    Am J Pathol 158:1491-502. 2001
    Development of noninvasive methods for the diagnosis of transitional cell carcinoma (TCC) of the bladder remains a challenge...
  62. ncbi Soluble form of carbonic anhydrase IX (CAIX) in transitional cell carcinoma of urinary tract
    L Hyrsl
    Department of Urology, Charles University 2nd Faculty of Medicine and Hospital Motol, Prague, Czech, Republic
    Neoplasma 56:298-302. 2009
    We investigated the expression of cell-associated CAIX protein in histological sections of the transitional cell carcinoma (TCC) of the urinary tract and of the soluble form of CAIX (s-CAIX) shed by the tumor into the serum and urine of ..
  63. ncbi K-RAS mutation in transitional cell carcinoma of urinary bladder
    S Ayan
    Department of Urology, Medical Biology and Genetics and Pathology, Faculty of Medicine, Cumhuriyet University, Sivas, Turkey
    Int Urol Nephrol 33:363-7. 2001
    In the present study it was aimed to investigate the frequency of K-RAS mutation in the human bladder transitional cell carcinoma. For this purpose, tissue specimens obtained from the patients with bladder tumors...
  64. ncbi Mutational analysis of the BRAF gene in transitional cell carcinoma of the bladder
    Ioannis Boulalas
    Department of Urology, Asklipieio General Hospital, Voula, Athens, Greece
    Int J Biol Markers 24:17-21. 2009
    ..The most frequent mutation in exon 15 (V600E) as well as several other mutations within exons 11 and 15 result in constitutive activation of the oncoprotein...
  65. ncbi A phase II trial of pemetrexed plus gemcitabine in locally advanced and/or metastatic transitional cell carcinoma of the urothelium
    H von der Maase
    Department of Oncology, Aarhus University Hospital, Aarhus C, Denmark
    Ann Oncol 17:1533-8. 2006
    ..study were to determine overall response rate (ORR), progression-free survival, overall survival and safety and toxicity in chemonaive patients with locally advanced and/or metastatic transitional cell carcinoma of the urothelium.
  66. ncbi Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses
    Yair Lotan
    Department of Urology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390 9110, USA
    Urology 61:109-18; discussion 118. 2003
    To determine the clinical utility of urine-based bladder tumor markers (UBBTMs) and cytology in the treatment of patients with transitional cell carcinoma on the basis of their statistical performance.
  67. ncbi Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells
    Peter C Black
    Department of Urology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 14:1478-86. 2008
    ..The aim of this study was to define molecular markers of response to cetuximab therapy in a panel of urothelial carcinoma cell lines...
  68. doi Promoter hypermethylation in tumour suppressor genes shows association with stage, grade and invasiveness of bladder cancer
    Sonata Jarmalaite
    Faculty of Natural Sciences, Vilnius University, Vilnius, Lithuania
    Oncology 75:145-51. 2008
    ....
  69. ncbi Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma
    K Sibley
    ICRF Clinical Centre, St James s University Hospital, Beckett Street, Leeds LS9 7TF, UK
    Oncogene 20:686-91. 2001
    4p16.3 has previously been identified as a region of non-random LOH in transitional cell carcinoma, suggesting the presence of a tumour suppressor gene. One candidate within this region is fibroblast growth factor receptor 3 (FGFR3)...
  70. ncbi Detection of circulating urothelial cancer cells in the blood using the CellSearch System
    Michio Naoe
    Department of Urology, School of Medicine, Showa University, Tokyo, Japan
    Cancer 109:1439-45. 2007
    ..The purpose of this study was to test the hypothesis that CTCs are detected in patients with urothelial cancers using newly developed CellSearch Assay...
  71. doi EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder
    Marko Babjuk
    Department of Urology, General Teaching Hospital, First Faculty of Medicine, Charles University, Praha, Czech Republic
    Eur Urol 54:303-14. 2008
    ..To present the updated version of 2008 European Association of Urology (EAU) guidelines on non-muscle-invasive bladder cancer...
  72. ncbi Carbonic anhydrase IX, a marker of hypoxia: correlation with clinical outcome in transitional cell carcinoma of the bladder
    Syed A Hussain
    Cancer Research UK Institute for Cancer Studies, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK
    Oncol Rep 11:1005-10. 2004
    ..examine expression of CA IX in archival tissues of patients included in various therapeutic trials for transitional cell carcinoma (TCC) of the bladder...
  73. ncbi The levels of glutathione peroxidase, vitamin A, E, C and lipid peroxidation in patients with transitional cell carcinoma of the bladder
    O Yalcin
    Department of Urology, Firat Medical Centre, and Department of Chemistry, Faculty of Science and Literature, Firat University, 23119 Elazig, Turkey
    BJU Int 93:863-6. 2004
    To assess the levels of erythrocyte glutathione peroxidase (GSH-Px), and the serum levels of antioxidant vitamins (A, E and C), selenium and malondialdehyde (MDA) in patients with transitional cell carcinoma (TCC) of the bladder.
  74. pmc Effects of short-term celecoxib treatment in patients with invasive transitional cell carcinoma of the urinary bladder
    Deepika Dhawan
    Department Veterinary Clinical Sciences, Purdue University, West Lafayette, IN 47907 2026, USA
    Mol Cancer Ther 9:1371-7. 2010
    High-grade invasive transitional cell carcinoma (InvTCC) kills >14,000 people yearly in the United States, and better therapy is needed. Cyclooxygenase-2 (Cox-2) is overexpressed in bladder cancer...
  75. ncbi Recurrence and survival following laparoscopic radical nephroureterectomy with various forms of bladder cuff control
    Surena F Matin
    Section of Laparoscopic and Minimally Invasive Surgery, Glickman Urological Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    J Urol 173:395-400. 2005
    We document recurrence and survival following laparoscopic radical nephroureterectomy (LNUX) for upper tract transitional cell carcinoma (TCC) using primarily 2 methods of managing the bladder cuff.
  76. ncbi Expression of cyclooxygenase-2 in normal urothelium, and superficial and advanced transitional cell carcinoma of bladder
    Vitaly Margulis
    Department of Urology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390 9110, USA
    J Urol 177:1163-8. 2007
    We compared the differential expression of cyclooxygenase-2 in normal bladder tissue, primary bladder transitional cell carcinoma and transitional cell carcinoma metastases to lymph nodes, and determined whether cyclooxygenase-2 ..
  77. ncbi FOLFOX-4 in pre-treated patients with advanced transitional cell carcinoma of the bladder
    Giuseppe Di Lorenzo
    Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Seconda Universita degli Studi, Naples, Italy
    Jpn J Clin Oncol 34:747-50. 2004
    ..We conducted a study using FOLFOX-4 (oxaliplatin, fluorouracil, folinic acid) in pre-treated advanced bladder cancer patients...
  78. pmc Distinct microRNA alterations characterize high- and low-grade bladder cancer
    James W F Catto
    Academic Urology Unit, University of Sheffield, Sheffield, United Kingdom
    Cancer Res 69:8472-81. 2009
    ..In conclusion, distinct microRNA alterations characterize UCC and target genes in a pathway-specific manner. These data reveal new insights into the disease biology and have implications regarding tumor diagnosis, prognosis and therapy...
  79. ncbi A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma
    Christian Wulfing
    Department of Urology, University of Munster, Munster, Germany
    Cancer 115:2881-90. 2009
    The treatment of recurrent transitional cell carcinoma (TCC) remains an unmet clinical need...
  80. ncbi HER-2/neu protein overexpression and gene amplification in human transitional cell carcinoma of the bladder
    Christopher L Coogan
    Department of Urology, Rush Medical College, Chicago, Illinois, USA
    Urology 63:786-90. 2004
    ..by fluorescence in situ hybridization and protein expression by immunohistochemistry in human bladder transitional cell carcinoma (TCC)...
  81. doi Comparative genomic hybridization study of arsenic-exposed and non-arsenic-exposed urinary transitional cell carcinoma
    Ling I Hsu
    The Genomics Research Center, Academia Sinica, Taipei, Taiwan
    Toxicol Appl Pharmacol 227:229-38. 2008
    To compare the differences in DNA aberrations between arsenic-exposed and non-arsenic-exposed transitional cell carcinoma (TCC), we analyzed 19 arsenic-exposed and 29 non-arsenic-exposed urinary TCCs from Chi-Mei Hospital using ..
  82. ncbi Silibinin causes cell cycle arrest and apoptosis in human bladder transitional cell carcinoma cells by regulating CDKI-CDK-cyclin cascade, and caspase 3 and PARP cleavages
    Alpana Tyagi
    Department of Pharmaceutical Sciences, School of Pharmacy, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    Carcinogenesis 25:1711-20. 2004
    ..Here, we assessed the effect of silibinin on human bladder transitional cell carcinoma (TCC) cell growth, cell cycle modulation and apoptosis induction, and associated molecular alterations, ..
  83. ncbi Laparoscopic distal ureterectomy and anastomosis for management of low-risk upper urinary tract transitional cell carcinoma: preliminary results
    Morgan Roupret
    Department of Urology, Institut Mutualiste Montsouris, University Rene Descartes, Paris V, 42 Boulevard Jourdan, 74014 Paris, France
    BJU Int 99:623-7. 2007
    To determine the surgical feasibility and early oncological outcomes of laparoscopic distal ureterectomy in patients with low-grade upper urinary tract transitional cell carcinoma (UUT-TCC).
  84. pmc A randomized trial comparing methotrexate and vinblastine (MV) with cisplatin, methotrexate and vinblastine (CMV) in advanced transitional cell carcinoma: results and a report on prognostic factors in a Medical Research Council study. MRC Advanced Bladder
    G M Mead
    Royal South Hants Hospital, Brintons Terrace, Southampton, UK
    Br J Cancer 78:1067-75. 1998
    ..and vinblastine (MV) with cisplatin, methotrexate and vinblastine (CMV) in advanced or metastatic transitional cell carcinoma was conducted in the UK...
  85. ncbi Seven years' experience with 5-aminolevulinic acid in detection of transitional cell carcinoma of the bladder
    Edwin Hungerhuber
    Department of Urology, Klinikum Grosshadern, Ludwig Maximilians University of Munich, Munich, Germany
    Urology 69:260-4. 2007
    ..5-aminolevulinic acid has proved to be a procedure with an outstanding sensitivity for the detection of transitional cell carcinoma of the bladder, in particular in the detection of flat urothelial lesions...
  86. doi Lymphovascular invasion and pT stage are prognostic factors in patients treated with radical nephroureterectomy for localized upper urinary tract transitional cell carcinoma
    Dong Suk Kim
    Department of Urology, Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea
    Urology 75:328-32. 2010
    To investigate the prognostic significance of lymphovascular invasion (LVI) in patients with localized upper urinary tract transitional cell carcinoma (UUT-TCC) after radical nephroureterectomy.
  87. ncbi Hand-assisted laparoscopic nephroureterectomy for upper urinary-tract transitional-cell carcinoma
    Ravi Munver
    The James Buchanan Brady Foundation, Department of Urology, The New York Presbyterian Hospital Weill Medical College of Cornell University, New York, New York 10021, USA
    J Endourol 18:351-8. 2004
    ..As operative times decrease, hand-assisted laparoscopic nephroureterectomy may become the procedure of choice for upper-tract transitional-cell carcinoma. The techniques and early results are described...
  88. ncbi Histologic tumor growth pattern is significantly associated with disease-related survival in muscle-invasive transitional cell carcinoma of the urinary bladder
    Stefan Kruger
    Institute of Pathology, University of Schleswig Holstein Campus Lubeck, Ratzeburger Allee 160, D 23538 Lubeck, Germany
    Oncol Rep 12:609-13. 2004
    ..The tumor growth classification proposed here may serve as an additional tool to predict the prognosis of patients undergoing radical cystectomy for bladder cancer...
  89. ncbi Management of clinical T1 bladder transitional cell carcinoma by radical cystectomy
    Fernando J Bianco
    Department of Urology, Wayne State University School of Medicine and Karmanos Cancer Institute, Detroit, MI, USA
    Urol Oncol 22:290-4. 2004
    ..For high-grade tumors, early cystectomy and orthotopic diversion increases life expectancy significantly and should be carry out early rather than late...
  90. ncbi Grade of hydronephrosis and tumor diameter as preoperative prognostic factors in ureteral transitional cell carcinoma
    Kang Su Cho
    Department of Urology and Urological Science Institute, Yonsei University College of Medicine, Seodaemun gu, Seoul, Korea
    Urology 70:662-6. 2007
    To evaluate the clinical significance of the grade of hydronephrosis and the tumor diameter in ureteral transitional cell carcinoma.
  91. ncbi Proteome-based diagnostics and prognosis of bladder transitional cell carcinoma
    Ting Feng Wu
    Southern Taiwan University, Department of Biotechnology, Tainan, Taiwan
    Expert Rev Proteomics 4:639-47. 2007
    More than 90% of bladder tumors are diagnosed as bladder transitional cell carcinoma and the majority of these lesions (70%) are diagnosed as superficial papillary lesions (stage pTa, T1)...
  92. ncbi Expression of uroplakin Ib and uroplakin III genes in tissues and peripheral blood of patients with transitional cell carcinoma
    T Yuasa
    Department of Urology, Shiga University of Medical Science, Otsu
    Jpn J Cancer Res 89:879-82. 1998
    ..These genes were also detected in the peripheral blood of 3 patients with metastatic transitional cell carcinoma (TCC), but not in that from 9 patients with non-metastatic TCC or 3 healthy volunteers...
  93. doi Photodynamic diagnosis (PDD) for upper urinary tract transitional cell carcinoma (UT-TCC): evolution of a new technique
    B K Somani
    Department of Urology, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK
    Photodiagnosis Photodyn Ther 7:39-43. 2010
    b>Transitional cell carcinoma of renal pelvis and ureter account was traditionally treated with nephroureterectomy...
  94. ncbi Results of inadvertent administration of bacillus Calmette-Guerin for treatment of transitional cell carcinoma of bladder
    Aliasghar Yarmohammadi
    Department of Urology, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran
    Urol J 4:121-2. 2007
  95. ncbi Independent predictors of cancer-specific survival in transitional cell carcinoma of the upper urinary tract: multi-institutional dataset from 3 European centers
    Giacomo Novara
    Department of Oncological and Surgical Sciences, Urology Clinic, University of Padua, Padua, Italy
    Cancer 110:1715-22. 2007
    The objective of the current study was to identify variables that were predictive of cancer-specific survival in patients with nonmetastatic transitional cell carcinoma of the upper urinary tract (UUT-TCC).
  96. ncbi Prognostic implications of lymphangiogenesis in muscle-invasive transitional cell carcinoma of the bladder
    Mario I Fernández
    Department of Urology, University Hospital Mannheim, Germany
    Eur Urol 53:571-8. 2008
    Aim of the study was to describe and evaluate the association of lymph vessel density with clinicopathological parameters and survival in patients with muscle-invasive transitional cell carcinoma (TCC) of the bladder.
  97. ncbi Effectiveness of adjuvant chemotherapy in transitional cell carcinoma of the urinary bladder with lymph node involvement and/or lymphovascular invasion treated by radical cystectomy
    Jinsung Park
    Department of Urology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea
    Urology 70:257-62. 2007
    To assess the effect of adjuvant chemotherapy on the postoperative survival of patients with transitional cell carcinoma of the bladder and lymph node involvement and/or lymphovascular invasion (LVI).
  98. ncbi Relation between cyclooxygenase-2 expression and clinicopathologic parameters with patient prognosis in transitional cell carcinoma of the bladder
    Serhat Gurocak
    Department of Urology, Gazi University School of Medicine, Ankara, Turkey
    Urol Int 76:51-6. 2006
    ..To evaluate the correlation between cyclooxygenase-2 (Cox-2) expression and clinicopathologic findings with the effect of these variables on prognosis of bladder cancer...
  99. ncbi BDNF mediated TrkB activation is a survival signal for transitional cell carcinoma cells
    Yen Ta Huang
    Institute of Pharmacology and Toxicology, Tzu Chi University, Hualien 970, Taiwan, R O C
    Int J Oncol 36:1469-76. 2010
    Pathologically, >90% of bladder cancer is transitional cell carcinoma (TCC). Previously, brain-derived neurotrophic factor (BDNF) but not tropomyosin-related kinase B (TrkB) was found in normal urothelium...
  100. ncbi Prognostic value of lymphovascular invasion in transitional cell carcinoma of upper urinary tract
    Bumsik Hong
    Department of Urology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
    Urology 65:692-6. 2005
    To elucidate the prognostic significance of lymphovascular invasion (LVI) in patients with upper tract transitional cell carcinoma.
  101. ncbi Solitary cystic cerebral metastasis from transitional cell carcinoma of the bladder
    Andreas Zigouris
    Department of Neurosurgery, University Hospital of Ioannina, Greece
    Acta Neurol Belg 109:322-5. 2009
    ..previous history entailed a total cystectomy and radical prostatectomy 7 months ago because of a transitional cell carcinoma (TCC) of the urinary bladder...

Research Grants73

  1. REAL TIME IN VIVO DIAGNOSIS OF DYSPLASIA BY FLUORESCENCE
    Michael Feld; Fiscal Year: 1999
    ..The techniques developed in this program will be clinically tested for rapid detection of colorectal dysplasia/carcinoma in chronic ulcerative colitis and other settings, and dysplasia/transitional cell carcinoma in the urinary bladder.
  2. Magnetic Resonance Spectroscopy of Tumors and Tissues
    Pamela Nurenberg; Fiscal Year: 2002
    ..tumors such as oncocytoma, and angiomyolipoma, and from other malignant lesions such as lymphoma, transitional cell carcinoma, and metastasis. C...
  3. Targeted siRNA nanotechnology for intravesical treatment of urologicaldiseases
    Robert Weiss; Fiscal Year: 2009
    ..biodegradable nanospheres provides wide opportunities for the treatment of urologic diseases including transitional cell carcinoma of the bladder (TCC), interstitial cystitis (IC), overactive bladder, and detrusor hyperreflexia...
  4. Targeted siRNA nanotechnology for intravesical treatment of urologicaldiseases
    Robert M Weiss; Fiscal Year: 2010
    ..biodegradable nanospheres provides wide opportunities for the treatment of urologic diseases including transitional cell carcinoma of the bladder (TCC), interstitial cystitis (IC), overactive bladder, and detrusor hyperreflexia...
  5. Telomere dysfunction, chromosome 9 instability and bladder cancer risk
    Yun Ling Zheng; Fiscal Year: 2010
    ..established that environmental exposures, particularly tobacco smoking, are important risk factors in transitional cell carcinoma (TCC) of the urinary bladder...
  6. Telomere dysfunction, chromosome 9 instability and bladder cancer risk
    Yun Ling Zheng; Fiscal Year: 2009
    ..established that environmental exposures, particularly tobacco smoking, are important risk factors in transitional cell carcinoma (TCC) of the urinary bladder...
  7. MCAV in Organ-Confined Bladder CA based on p53 Status
    Richard Cote; Fiscal Year: 2003
    This is a renewal application to our on-going "p53/MVAC" study. Tumor progression in transitional cell carcinoma (TCC) of the urinary bladder is believed to occur through a multistep accumulation of genetic alterations...
  8. MCAV in Organ-Confined Bladder CA based on p53 Status
    Richard Cote; Fiscal Year: 2004
    This is a renewal application to our on-going "p53/MVAC" study. Tumor progression in transitional cell carcinoma (TCC) of the urinary bladder is believed to occur through a multistep accumulation of genetic alterations...
  9. MCAV in Organ-Confined Bladder CA based on p53 Status
    Richard Cote; Fiscal Year: 2005
    This is a renewal application to our on-going "p53/MVAC" study. Tumor progression in transitional cell carcinoma (TCC) of the urinary bladder is believed to occur through a multistep accumulation of genetic alterations...
  10. MCAV in Organ-Confined Bladder CA based on p53 Status
    Richard Cote; Fiscal Year: 2006
    ..Tumor progression in transitional cell carcinoma (TCC) of the urinary bladder is believed to occur through a multistep accumulation of genetic ..
  11. Rapid release paclitaxel nanoparticles for bladder cancer intravestical therapy
    Ze Lu; Fiscal Year: 2009
    ..b>Transitional cell carcinoma accounts for more than 90% of bladder cancers...
  12. Rapid release paclitaxel nanoparticles for bladder cancer intravestical therapy
    Ze Lu; Fiscal Year: 2009
    ..b>Transitional cell carcinoma accounts for more than 90% of bladder cancers...
  13. Chemoprevention of urinary bladder carcinogenesis by flavokawain A
    Xiaolin Zi; Fiscal Year: 2010
    ..mouse models each which induces a separate precursor state to advanced bladder cancer: either papillary transitional cell carcinoma or carcinoma in situ. In addition, we will validate potential transcriptional targets (i.e...
  14. Chemoprevention of urinary bladder carcinogenesis by flavokawain A
    Xiaolin Zi; Fiscal Year: 2009
    ..mouse models each which induces a separate precursor state to advanced bladder cancer: either papillary transitional cell carcinoma or carcinoma in situ. In addition, we will validate potential transcriptional targets (i.e...
  15. Chemoprevention of urinary bladder carcinogenesis by flavokawain A
    Xiaolin Zi; Fiscal Year: 2010
    ..mouse models each which induces a separate precursor state to advanced bladder cancer: either papillary transitional cell carcinoma or carcinoma in situ. In addition, we will validate potential transcriptional targets (i.e...
  16. PROTEASE INHIBITORS IN HUMAN BLADDER CANCER INVASION
    Brian Liu; Fiscal Year: 1991
    ..To study the biochemical mechanisms of bladder tumor invasion, we have previously analyzed invasive transitional cell carcinoma cell line EJ and non-invasive transitional cell carcinoma cell line RT4 which had been implanted into ..
  17. PROTEASE INHIBITORS IN HUMAN BLADDER CANCER INVASION
    Brian Liu; Fiscal Year: 1993
    ..To study the biochemical mechanisms of bladder tumor invasion, we have previously analyzed invasive transitional cell carcinoma cell line EJ and non-invasive transitional cell carcinoma cell line RT4 which had been implanted into ..
  18. MVAC IN BLADDER CANCER BASED ON P53 STATUS
    Richard Cote; Fiscal Year: 1999
    ..David Esrig, plans to build on previous laboratory and preliminary clinical data. Tumor progression in transitional cell carcinoma (TCC) of the urinary bladder is believed to occur through a multistep accumulation of genetic ..
  19. Antiestrogen Regulation of Bladder Cancer
    Carolyn Smith; Fiscal Year: 2009
    ..Experiments employing ligand binding analyses indicate that ERs are present in transitional cell carcinoma of bladder in humans, and immunological approaches demonstrate ERa expression in 12%-18% of tested ..
  20. MULTIDIMENSIONAL SLIT-SCAN DETECTION OF BLADDER CANCER
    LEON WHEELESS; Fiscal Year: 1990
    ..the use of quantitative techniques to: 1) improve the sensitivity and specificity of the detection of transitional cell carcinoma and its precursors in the urinary bladder, 2) improve the clinical management of patients through the ..
  21. Investigating the role of p73 and its isoforms in tumorigenesis and metastasis
    Elsa R Flores; Fiscal Year: 2010
    ..Data from some human tumors, including lung adenocarcinoma, transitional cell carcinoma of the bladder, osteosarcoma, mammary adenocarcinoma and myelogenous leukemia, indicate that loss of ..
  22. Investigating the role of p73 and its isoforms in tumorigenesis and metastasis
    ELSA FLORES; Fiscal Year: 2009
    ..Data from some human tumors, including lung adenocarcinoma, transitional cell carcinoma of the bladder, osteosarcoma, mammary adenocarcinoma and myelogenous leukemia, indicate that loss of ..
  23. INTRAVESICAL BCG FOR BLADDER CANCER--ROLE OF FIBRONECTIN
    Timothy Ratliff; Fiscal Year: 1990
    Surgical adjuvant intravesical bacille Calmette-Guerin (BCG) is the treatment of choice for superficial transitional cell carcinoma of the bladder...
  24. Identification, Characterization and Enrichment of Adult Urothelial Stem Cells
    ERIC ABRAHAM KURZROCK; Fiscal Year: 2010
    ..This will lead to further study of cancer stem cells and better treatments for transitional cell carcinoma. PUBLIC HEALTH RELEVANCE: Stem cells carry a tissue's regenerative potential for the life of the ..
  25. Identification, Characterization and Enrichment of Adult Urothelial Stem Cells
    ERIC KURZROCK; Fiscal Year: 2009
    ..This will lead to further study of cancer stem cells and better treatments for transitional cell carcinoma. PUBLIC HEALTH RELEVANCE: Stem cells carry a tissue's regenerative potential for the life of the ..
  26. PROSTATE ULTRASONOGRAPHY AND BIOCHEMICAL PROFILE
    Martin Resnick; Fiscal Year: 1992
    ..radical prostatectomy for known adenocarcinoma of the prostate and radical cystoprostatectomy for known transitional cell carcinoma of the urinary bladder...
  27. SLIT SCAN DETECTION OF BLADDER CANCER
    LEON WHEELESS; Fiscal Year: 1999
    ..development and progression, and provide information on clinical course for patients with superficial transitional cell carcinoma. The goal will be met through four specific aims: l) Test the hypothesis that chromosome 9 aberrations ..
  28. Biomarker Reference Laboratory, EDRN
    William Grizzle; Fiscal Year: 2006
    ..of the validation study of using microsatellite analysis of urine sediment in the early detection of transitional cell carcinoma of the bladder and as the primary validation laboratory of the Validation Study of the use of SELDI-TOF-..
  29. Biomarker Reference Laboratory, EDRN
    William Grizzle; Fiscal Year: 2005
    ..of the validation study of using microsatellite analysis of urine sediment in the early detection of transitional cell carcinoma of the bladder and as the primary validation laboratory of the Validation Study of the use of SELDI-TOF-..
  30. Biomarker Reference Laboratory, EDRN
    William Grizzle; Fiscal Year: 2007
    ..of the validation study of using microsatellite analysis of urine sediment in the early detection of transitional cell carcinoma of the bladder and as the primary validation laboratory of the Validation Study of the use of SELDI-TOF-..
  31. Biomarker Reference Laboratory, EDRN
    William E Grizzle; Fiscal Year: 2010
    ..of the validation study of using microsatellite analysis of urine sediment in the early detection of transitional cell carcinoma of the bladder and as the primary validation laboratory of the Validation Study of the use of SELDI-TOF-..
  32. Biomarker Reference Laboratory, EDRN
    William Grizzle; Fiscal Year: 2009
    ..of the validation study of using microsatellite analysis of urine sediment in the early detection of transitional cell carcinoma of the bladder and as the primary validation laboratory of the Validation Study of the use of SELDI-TOF-..
  33. Pilot Study--Cox2 Inhibitor in Invasive Bladder Cancer
    DEBORAH KNAPP; Fiscal Year: 2001
    ..Most of those deaths are due to invasive transitional cell carcinoma (TCC) that has metastasized and is resistant to chemotherapy...
  34. Pilot Study--Cox2 Inhibitor in Invasive Bladder Cancer
    DEBORAH KNAPP; Fiscal Year: 2002
    ..Most of those deaths are due to invasive transitional cell carcinoma (TCC) that has metastasized and is resistant to chemotherapy...
  35. Metallothionein Isoform 3 as a Urinary Marker for Bladder Cancer
    Donald Sens; Fiscal Year: 2009
    ..The tumor heterotransplants generated from these transformants displayed the histology expected of transitional cell carcinoma of the bladder...
  36. Metallothionein Isoform 3 as a Urinary Marker for Bladder Cancer
    Donald Sens; Fiscal Year: 2007
    ..The tumor heterotransplants generated from these transformants displayed the histology expected of transitional cell carcinoma of the bladder...
  37. Metallothionein Isoform 3 as a Urinary Marker for Bladder Cancer
    Donald Sens; Fiscal Year: 2007
    ..The tumor heterotransplants generated from these transformants displayed the histology expected of transitional cell carcinoma of the bladder...
  38. EPIDERMAL GROWTH FACTOR RECEPTOR IN BLADDER CANCER
    Menashe Bar Eli; Fiscal Year: 2001
    Epidermal growth factor receptor (EGF-R) regulates the growth of human transitional cell carcinoma (TCC) of the bladder in part, by regulating the expression of the matrix metalloproteinase MMP-9...
  39. Metallothionein Isoform 3 Urinary Marker Bladder Cancer
    Donald Sens; Fiscal Year: 2006
    ..The tumor heterotransplants generated from these transformants displayed the histology expected of transitional cell carcinoma of the bladder...
  40. Capsaicin for chemoprevention of transition cell carcinoma of the bladder
    Rita Ghosh; Fiscal Year: 2009
    DESCRIPTION (provided by applicant): Transitional cell carcinoma of the bladder is a highly recurrent and the most common form of bladder cancer in the United States. It is very expensive to monitor and treat this form of bladder cancer...
  41. VOLUME MICROPROBE TM ASSISTED BLADDER BIOPSY
    Robert Nordstrom; Fiscal Year: 1999
    Approximately 40,000 new cases of early stage transitional cell carcinoma (TCCA) present annually in the US. Over 30,000 are superficial; 75% recur; 10-15% progress to invasion...
  42. IN-VIVO AND IN-VITRO TUMOR LYSIS BY TNF PRODUCING CELLS
    Edmund Lattime; Fiscal Year: 1991
    ..Intravesical administration of Bacillus Calmette Guerin (BCG) for superficial transitional cell carcinoma (TCC) of the bladder has proven the most effective anti-tumor immunotherapy to date, however, its ..
  43. IN-VIVO AND IN-VITRO TUMOR LYSIS BY TNF PRODUCING CELLS
    Edmund Lattime; Fiscal Year: 1993
    ..Intravesical administration of Bacillus Calmette Guerin (BCG) for superficial transitional cell carcinoma (TCC) of the bladder has proven the most effective anti-tumor immunotherapy to date, however, its ..
  44. Magnetic Resonance Spectroscopy of Tumors and Tissues
    Pamela Nurenberg; Fiscal Year: 2001
    ..tumors such as oncocytoma, and angiomyolipoma, and from other malignant lesions such as lymphoma, transitional cell carcinoma, and metastasis. C...
  45. The role of CAR and its application in bladder cancer
    Jer Tsong Hsieh; Fiscal Year: 2003
    ..Variable morphology, natural history, and prognosis demonstrate that transitional cell carcinoma (TCC) of the bladder is not a single disease, but occurs in three distinct forms, each possessing ..
  46. Effect of G-CSFR expression in bladder cancer
    Arup Chakraborty; Fiscal Year: 2004
    ..Our aim is to clearly demonstrate that G-CSF expression coupled with aberrant G-CSFR expression by transitional cell carcinoma (TCC) can be used as a predictor of more aggressive behavior...
  47. Effect of G-CSFR expression in bladder cancer
    Arup Chakraborty; Fiscal Year: 2005
    ..Our aim is to clearly demonstrate that G-CSF expression coupled with aberrant G-CSFR expression by transitional cell carcinoma (TCC) can be used as a predictor of more aggressive behavior...
  48. The role of CAR and its application in bladder cancer
    Jer Tsong Hsieh; Fiscal Year: 2006
    ..Variable morphology, natural history, and prognosis demonstrate that transitional cell carcinoma (TCC) of the bladder is not a single disease, but occurs in three distinct forms, each possessing ..
  49. Determining the mechanistic and therapeutic roles of microRNAs in bladder cancer
    GANGNING NONE LIANG; Fiscal Year: 2010
    ..Bladder cancer, which usually presents as transitional cell carcinoma (TCC), is the fifth most common cancer in the United States...
  50. Identification of Genes Involved in Bladder Cancer
    John Clifford; Fiscal Year: 2006
    unreadable] DESCRIPTION (provided by applicant): Project Summary: Transitional cell carcinoma of the bladder (TCC) ranks 4th in incidence of all cancers in the developed world, yet the mechanisms of its origin and progression remain ..
  51. Identification of Genes Involved in Bladder Cancer
    John Clifford; Fiscal Year: 2007
    unreadable] DESCRIPTION (provided by applicant): Project Summary: Transitional cell carcinoma of the bladder (TCC) ranks 4th in incidence of all cancers in the developed world, yet the mechanisms of its origin and progression remain ..
  52. METALLOTHIONEIN & HUMAN TUMOR RESISTANCE TO CHEMOTHERAPY
    Marc Ernstoff; Fiscal Year: 1990
    ..of MT on tumor resistance, we propose to measure the cellular expression of MT in two human cancers: transitional cell carcinoma of the urinary bladder and squamous cell carcinoma of the head and neck...
  53. Hedgehog signaling links bladder injury and cancer
    David Berman; Fiscal Year: 2009
    ..4) To test whether continuously enforced Hh signaling is sufficient to induce urothelial carcinogenesis. ..
  54. Hedgehog signaling links bladder injury and cancer
    DAVID MONTY BERMAN; Fiscal Year: 2010
    ..4) To test whether continuously enforced Hh signaling is sufficient to induce urothelial carcinogenesis. ..
  55. Hedgehog signaling links bladder injury and cancer
    David Berman; Fiscal Year: 2006
    ..4) To test whether continuously enforced Hh signaling is sufficient to induce urothelial carcinogenesis. [unreadable] [unreadable] [unreadable]..
  56. Hedgehog signaling links bladder injury and cancer
    David Berman; Fiscal Year: 2009
    ..4) To test whether continuously enforced Hh signaling is sufficient to induce urothelial carcinogenesis. ..
  57. Hedgehog signaling links bladder injury and cancer
    David Berman; Fiscal Year: 2007
    ..4) To test whether continuously enforced Hh signaling is sufficient to induce urothelial carcinogenesis. ..
  58. Parallel OCT System for Endoscopic Imaging
    Jennifer Barton; Fiscal Year: 2003
    ..4. Determine the ability of the I I OCT system to accurately determine the stage of transitional cell carcinoma of the bladder...
  59. Parallel OCT System for Endoscopic Imaging
    Jennifer Barton; Fiscal Year: 2002
    ..4. Determine the ability of the I I OCT system to accurately determine the stage of transitional cell carcinoma of the bladder...
  60. Parallel OCT System for Endoscopic Imaging
    Jennifer Barton; Fiscal Year: 2004
    ..4. Determine the ability of the I I OCT system to accurately determine the stage of transitional cell carcinoma of the bladder...
  61. CISPLATIN PLUS PACLITAXEL IN ADVANCED CARCINOMA OF THE UROTHELIUM
    Howard Hochster; Fiscal Year: 1999
    ..abstract_text> ..
  62. MOLECULAR MECHANISMS OF HUMAN BLADDER CARCINOGENESIS
    Peter Jones; Fiscal Year: 2004
    ..bladder cancer databases to further understand the etiology, diagnosis and prognosis of transitional cell carcinoma of the bladder...
  63. HUMAN ANTITUMOR EFFECTOR MECHANISMS
    Edmund Lattime; Fiscal Year: 1999
    ..Assess the interaction between tumor and the host immune cells in patients with transitional cell carcinoma of the bladder; 2. Assess the effects of inhibition of IL-10 on TCC growth and antigen expression; 3...
  64. MOLECULAR MECHANISMS OF HUMAN BLADDER CARCINOGENESIS
    Peter Jones; Fiscal Year: 2002
    ..bladder cancer databases to further understand the etiology, diagnosis and prognosis of transitional cell carcinoma of the bladder...
  65. MOLECULAR MECHANISMS OF HUMAN BLADDER CARCINOGENESIS
    Peter Jones; Fiscal Year: 2005
    ..bladder cancer databases to further understand the etiology, diagnosis and prognosis of transitional cell carcinoma of the bladder...
  66. HUMAN ANTITUMOR EFFECTOR MECHANISMS
    Edmund Lattime; Fiscal Year: 2000
    ..Assess the interaction between tumor and the host immune cells in patients with transitional cell carcinoma of the bladder; 2. Assess the effects of inhibition of IL-10 on TCC growth and antigen expression; 3...
  67. HUMAN ANTITUMOR EFFECTOR MECHANISMS
    Edmund Lattime; Fiscal Year: 2001
    ..Assess the interaction between tumor and the host immune cells in patients with transitional cell carcinoma of the bladder; 2. Assess the effects of inhibition of IL-10 on TCC growth and antigen expression; 3...